Podcast Summary: Healthier World with Quest Diagnostics

Episode: Instant Insights: Apolipoprotein B
Host/Speaker: Dr. Mason Latsko
Release Date: September 24, 2024
Length: 7 minutes

Overview

This episode provides a concise, clinically focused insight into Apolipoprotein B (ApoB) and its critical role in cardiovascular risk assessment. Dr. Mason Latsko discusses why traditional lipid panels can sometimes underestimate risk, the importance of particle numbers in atherogenesis, the concept of discordance, and current guidelines supporting ApoB testing for more accurate risk stratification.

Key Discussion Points and Insights

1. Cardiovascular Disease: The Scope of the Problem

• Cardiovascular disease (CVD) remains the number one killer globally, claiming more lives than all cancers combined.
• The risk for CVD is still significantly under-identified:
  • "The first sign and symptom of disease is death in 64% of women and 50% of men." (01:06)

2. Limitations of LDL Cholesterol (LDL-C) in Risk Assessment

• LDL-C is the standard marker for identifying cardiovascular risk and dictating treatment.
• Yet, there is a major limitation:
  • "50% of patients hospitalized with coronary artery disease have normal LDL C levels." (01:29)

3. Introducing Lipoproteins and Apolipoprotein B

• Lipid panels measure cholesterol and triglyceride concentrations, but these molecules are hydrophobic and must travel in the blood via lipoproteins.
• Every non-HDL, atherogenic particle contains one ApoB molecule.
  • "Each atherogenic particle or non HDL particle carries exactly one APOB molecule on it. Thus, APOB levels correspond to the total number of atherogenic particles in circulation." (02:28)

4. Why ApoB Matters: Particle Number vs. Cholesterol Content

• Individuals with similar LDL cholesterols can have different cardiovascular risks because:

  • "It is the lipoprotein particles that can get trapped in the artery wall and lead to atherosclerotic buildup." (02:50)

• Analogy for Understanding:

  • "If cholesterol represents the people needing to be transported to an event and APOB represents the number of cars that are needed to get them there, we hope that people will carpool...We want our cholesterol to be packaged efficiently into particles...so there can be less particles in circulation and less risk for atherogenic progression." (03:30)

5. Understanding Discordance

• Definition: Discordance refers to a mismatch between LDL-C and ApoB particle counts.
• Example:
  • Patient with LDL-C = 100 mg/dL (20th percentile); ApoB = 103 mg/dL (60th percentile)
  • "This means that cholesterol is not packaged efficiently and there are significantly more particles needed to transport LDL cholesterol. These particles are small, dense and more atherogenic." (04:15)
  • "Given that risk tracks with particle count and quality, this person is at greater risk for cardiovascular disease and events." (04:30)

6. Who Is at Greater Risk for Increased Particle Count and Discordance?

• Driven by metabolic dysfunction and insulin resistance:
  • Obesity
  • Metabolic syndrome
  • Diabetes
  • Hypertriglyceridemia (05:00)
• Discordance also occurs in patients on lipid-lowering therapies, since LDL-C reductions may outpace ApoB decreases.

7. ApoB Outperforms LDL-C and Non-HDL-C

• "APOB outperforms LDL C and non HDL C as a predictor of cardiovascular disease events. This is particularly relevant in individuals who show discordance, indicating that LDL C may underestimate the risk in these individuals." (05:20)
• Recent data shows ApoB can identify people with 50% greater risk for myocardial infarction beyond what is expected using LDL-C alone.
• "Additionally, APOB levels are associated with residual cardiovascular risk and all cause mortality in patients on statin therapy." (05:40)

8. Professional Guidelines and Recommendations

• ApoB testing is now widely recommended by:
  • American Heart Association
  • American College of Cardiology
  • American Association of Clinical Endocrinology
  • National Lipid Association
  • European Society of Cardiology (06:00)
• Especially valuable for those:
  • With borderline/high 10-year ASCVD risk
  • At risk for metabolic dysfunction/discordance (e.g., insulin resistance, high triglycerides, obesity, type 2 diabetes)

9. Summary and Call to Action

• Cardiovascular risk is multifaceted, but ApoB provides a powerful, particle-based measure that identifies lipid-driven risk more precisely.
• "With the utility of cutting-edge technology to provide a comprehensive assessment, Quest Diagnostics aims to create a healthier world, one life at a time." (06:47)

Notable Quotes & Memorable Moments

• "The first sign and symptom of disease is death in 64% of women and 50% of men." — Dr. Mason Latsko (01:06)
• "50% of patients hospitalized with coronary artery disease have normal LDL C levels." (01:29)
• "Given that risk tracks with particle count and quality, this person is at greater risk for cardiovascular disease and events." (04:30)
• "APOB outperforms LDL C and non HDL C as a predictor of cardiovascular disease events." (05:20)
• "Each societal recommendation highlights APOB as the preferred measure of cardiovascular risk when testing is available." (06:10)

Key Timestamps for Important Segments

• 00:18 — Introduction to cardiovascular risk and traditional measures
• 01:50 — Explanation of lipoproteins and ApoB biology
• 03:00 — Analogy: cholesterol vs. ApoB (carpooling)
• 04:05 — Patient example illustrating discordance
• 05:00 — Who is at risk for increased particle count
• 05:20 — ApoB as a superior risk predictor
• 06:00 — Summary of professional guideline endorsements

Tone and Approach

Dr. Latsko’s explanations are clear, focused, and aim for immediate clinical relevance—bridging technical concepts with vivid analogies and actionable insights for health care professionals concerned with precision risk assessment.